Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ravi Salgia

Showing results (81-90 of 528) with videos related to

Pageof 53
Sort By:
JCO Oncology Practice|July 10, 2020
Progressive Neurologic Changes in a Patient With Metastatic Non-Small-Cell Lung Cancer: Cancer Effects or a Secondary Diagnosis?Idoroenyi Amanam, Isa Mambetsariev, Rohan Gupta, et al.
Expert Opinion on Biological Therapy|November 4, 2011
Role of MetMAb (OA-5D5) in c-MET active lung malignanciesMosmi Surati, Premal Patel, Amy Peterson, et al.
Advances in Experimental Medicine and Biology|December 3, 2013
A personalized treatment for lung cancer: molecular pathways, targeted therapies, and genomic characterizationThomas Hensing, Apoorva Chawla, Rishi Batra, et al.
Clinical Lung Cancer|March 27, 2007
Key signaling pathways and targets in lung cancer therapyNicholas W Choong, Ravi Salgia, Everett E Vokes
Future Oncology (London, England)|February 17, 2018
The brigatinib experience: a new generation of therapy for ALK-positive non-small-cell lung cancerIdoroenyi Amanam, Rohan Gupta, Isa Mambetsariev, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 29, 2002
CD2 molecules redistribute to the uropod during T cell scanning: implications for cellular activation and immune surveillanceElena V Tibaldi, Ravi Salgia, Ellis L Reinherz
Trends in Cancer|February 8, 2023
Precision oncology provides opportunities for targeting KRAS-inhibitor resistanceMartin Sattler, Atish Mohanty, Prakash Kulkarni, et al.
International Journal of Biological Macromolecules|August 5, 2022
Intrinsically disordered BMP4 morphogen and the beak of the finch: Co-option of an ancient axial patterning systemPrakash Kulkarni, Atish Mohanty, Ravi Salgia, et al.
Journal for Immunotherapy of Cancer|January 24, 2018
Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerationsJun Gong, Alexander Chehrazi-Raffle, Srikanth Reddi, et al.
BMC Cancer|March 23, 2018
Effective osimertinib treatment in a patient with discordant T790 M mutation detection between liquid biopsy and tissue biopsyIsa Mambetsariev, Lalit Vora, Kim Wai Yu, et al.
Pageof 53

Showing results (81-90 of 528) with videos related to

Sort By:
Pageof 53
JCO Oncology Practice|July 10, 2020
Progressive Neurologic Changes in a Patient With Metastatic Non-Small-Cell Lung Cancer: Cancer Effects or a Secondary Diagnosis?Idoroenyi Amanam, Isa Mambetsariev, Rohan Gupta, et al.
Expert Opinion on Biological Therapy|November 4, 2011
Role of MetMAb (OA-5D5) in c-MET active lung malignanciesMosmi Surati, Premal Patel, Amy Peterson, et al.
Advances in Experimental Medicine and Biology|December 3, 2013
A personalized treatment for lung cancer: molecular pathways, targeted therapies, and genomic characterizationThomas Hensing, Apoorva Chawla, Rishi Batra, et al.
Clinical Lung Cancer|March 27, 2007
Key signaling pathways and targets in lung cancer therapyNicholas W Choong, Ravi Salgia, Everett E Vokes
Future Oncology (London, England)|February 17, 2018
The brigatinib experience: a new generation of therapy for ALK-positive non-small-cell lung cancerIdoroenyi Amanam, Rohan Gupta, Isa Mambetsariev, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 29, 2002
CD2 molecules redistribute to the uropod during T cell scanning: implications for cellular activation and immune surveillanceElena V Tibaldi, Ravi Salgia, Ellis L Reinherz
Trends in Cancer|February 8, 2023
Precision oncology provides opportunities for targeting KRAS-inhibitor resistanceMartin Sattler, Atish Mohanty, Prakash Kulkarni, et al.
International Journal of Biological Macromolecules|August 5, 2022
Intrinsically disordered BMP4 morphogen and the beak of the finch: Co-option of an ancient axial patterning systemPrakash Kulkarni, Atish Mohanty, Ravi Salgia, et al.
Journal for Immunotherapy of Cancer|January 24, 2018
Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerationsJun Gong, Alexander Chehrazi-Raffle, Srikanth Reddi, et al.
BMC Cancer|March 23, 2018
Effective osimertinib treatment in a patient with discordant T790 M mutation detection between liquid biopsy and tissue biopsyIsa Mambetsariev, Lalit Vora, Kim Wai Yu, et al.
Pageof 53